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Abstract
Oxidative stress is believed to be one of the major factors behind several acute and chronic diseases, and may
also be associated with ageing. Excess formation of free radicals in miscellaneous body environment may
originate from endogenous response to cell injury, but also from exposure to a number of exogenous toxins.
When the antioxidant defence system is overwhelmed, this leads to cell damage. However, the measurement of
free radicals or their endproducts is tricky, since these compounds are reactive and short lived, and have
diverse characteristics. Specific evidence for the involvement of free radicals in pathological situations has
been difficult to obtain, partly owing to shortcomings in earlier described methods for the measurement of
oxidative stress. Isoprostanes, which are prostaglandin-like bioactive compounds synthesized in vivo from
oxidation of arachidonic acid, independently of cyclooxygenases, are involved in many human diseases, and
their measurement therefore offers a way to assess oxidative stress. Elevated levels of F2-isoprostanes have
also been seen in the normal human pregnancy, but their physiological role has not yet been defined. Large
amounts of bioactive F2-isoprostanes are excreted in the urine in normal basal situations, with a wide
interindividual variation. Their exact role in the regulation of normal physiological functions, however, needs
to be explored further. Current understanding suggests that measurement of F2-isoprostanes in body fluids
provides a reliable analytical tool to study oxidative stress-related diseases and experimental inflammatory
conditions, and also in the evaluation of various dietary antioxidants, as well as drugs with radical-scavenging
properties. However, assessment of isoprostanes in plasma or urine does not necessarily reflect any specific
tissue damage, nor does it provide information on the oxidation of lipids other than arachidonic acid.
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Introduction
O
ne of the major common features of acute
and chronic diseases, which cause high
morbidity and mortality globally, is the
surplus formation of various free radicals (reactive
oxygen or nitrogen species). These can origi-
nate from reactions to cell injury in general,
incorrect activation of phagocytic cells in chronic
inflammatory situations, diminished levels of anti-
oxidants, etc. Free radicals are formed endogen-
ously within the cell during diverse metabolic
processes in vivo, and can also be formed endogen-
ously upon exposure of the body to a number of
toxins, pesticides, pharmaceutical agents, environ-
ment pollutants, radiation injury, etc. However, the
formation of free radicals is also an indispensable
part of normal cell metabolism. Once biosynthe-
sized, these molecules may serve as bioregulators of
several functions of the body through signal trans-
duction, thus involving diverse biochemical pro-
cesses. This leads to further exclusive formation of
new biomolecules that are necessary to maintain
normal homoeostasis, signal transduction and pro-
tein function, and to ensure cell survival.
However, the measurement of free radicals or
their endproducts is difficult, particularly since
the free radicals are very reactive and spontane-
ously short lived. Therefore, scientists have primar-
ily focused on the detection of endproducts or their
by-products, which have quite diverse charac-
teristics. In 1989, William A. Pryor, Co-Editor-in
Chief of Free Radical Biology and Medicine, cited:
‘‘One of the greatest needs in this field now is the
availability of non-invasive tests to probe oxidative
stress status in humans’’. The lack of such tests has
been a major obstacle not only in exploring the
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diseases, but also in evaluating the epidemiological
findings regarding vitamins and diseases and in
designing a rationale for therapeutic targets against
the free radical-mediated diseases. Such data are
needed to resolve the constant debate on the role of
antioxidants in various diseases.
Isoprostanes are a newly discovered group of
prostaglandin-like compounds, which are bio-
synthesized from esterified arachidonic acid
through a non-enzymic free radical-catalysed me-
chanism and have very short half-lives (16 min in
humans and about 4 min in rabbits) (13). Several
of these compounds retain biological activities, as
confirmed mainly by pulmonary and vasoconstric-
tive, and even inflammatory activities (2, 3). Both
human and experimental studies reveal that iso-
prostanes are augmented in both acute and severe
chronic inflammation, ischaemiareperfusion, dia-
betes, atherosclerosis, obesity, lung and liver dis-
eases, etc (see Table 1). Furthermore, existing
evidences advocate that isoprostanes are authentic
indicators of free radical-mediated lipid peroxida-
tion and oxidative stress (2, 4). Having potent
biological activities and also involvement in both
normal physiology and pathophysiology, the mea-
surement of these compounds has attracted huge
attention, evident from an exponential increase in
the number of publications in the field since mid-
1990s. However, it is to be remembered that
assessment of isoprostanes in plasma or urine does
not necessarily provide information on any specific
tissue damage unless it is performed in certain tissue
or fluids collected from the tissue in question, and it
does not reflect oxidation of lipids other than
arachidonic acid.
Lipid peroxidation in relation to oxidative
stress
In a wider designation, lipid peroxidation in the
organic systems involves all oxidation of fatty acids
that occurs in vivo. Lipid peroxidation can occur
rapidly in the body through both enzymic and non-
enzymic reactions, the latter being primarily focused
in most studies. The enzymic pathway is well
documented in the oxidation of arachidonic acid
through cyclooxygenases and lipoxygenases with the
formation of bioactive prostaglandins, leukotrienes
or lipoxins, respectively (57). This review will
primarily cover free radicals mediated by non-
enzymic lipid oxidation products. One important
reason for the key roles of these free radicals is the
fact that free radical-catalysed oxidized lipids can
instantly modify the cell membrane fluidity, which
in turn can interact with the different membrane-
adhering enzymes and membrane-bound receptors.
In addition, many of these oxidized lipids may
possess bioactivity as vasodilators or vasoconstric-
tors/bronchoconstrictors, or induce inflammation in
neighbouring cells (see below).
It is well acknowledged that polyunsaturated fatty
acids (PUFAs) with two or more double bonds are
more prone to oxidation than the saturated and
monounsaturated fatty acids (8). This is largely due
to the instability (weak energy of attachment) of the
hydrogen atom adjoining the double bond. This
means that the hydrogen atom can be abstracted
easily through a reactive radical attack (Fig. 1).
Lipid peroxidation in vivo requires a PUFA and an
oxidant inducer, which form a free radical inter-
mediate. The free radical intermediate reacts with
oxygen to form a peroxyl radical (LOO). The
unpaired electrons of the peroxyl radicals further
abstract a hydrogen atom from another PUFA to
formalipidhydroperoxide,whichmaydecaytoform
alkoxyl or peroxyl radicals. These radicals may also
attract adjoining diverse membrane proteins. The
reaction of the peroxyl radical with other fatty acids
generates a carbon-centred radical which, in turn,
will be able to react with oxygen to form another
peroxyl radical. This radical continues its reaction to
the PUFAs, and a propagation reaction initiates a
chain reaction that is maintained until a termination
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Fig. 1. Basic principle of non-enzymic lipid peroxidation involving
polyunsaturated fatty acids.
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breaking antioxidants or by exogenously applied
antioxidants, dietary radical scavengers or drugs (9).
However, excess endogenous formation or exogen-
ous administration of these biocombating factors
may also lead to pro-oxidative effects in certain
conditions which, so far, have been less studied.
The oxidative reaction processes are often per-
ceived as being merely destructive in nature. How-
ever, they are also crucial elements of normal
human body functions, as essential actors in
biochemical reactions involved in the control of
physiological functions such as cell signalling,
vascular tone, cell generation and degeneration,
and defence against microorganisms (1014). The
physiologically essential reactive species seem to
be necessary to maintain the normal basal oxi-
dantantioxidant balance and host defences in
the mammalian system. However, when a surplus
formation of these bioactive oxidation products
exceeds the capacity of endogenous cellular anti-
oxidant defence mechanisms, these products may
intricate in various cell and organ damage by
upsetting the normal physiology in such a fashion
that they instigate and/or speed up the disease
processes. Furthermore, overstressed or damaged
cells in disease conditions will perhaps initiate the
production of these active compounds in vivo and
consequently inflate cellular or damage that po-
tentiates the disease process.
Isoprostanes as biomarker of in vivo lipid
peroxidation
Indications of non-enzymically auto-oxidized pro-
staglandin-resembling substances arising from
unsaturated fatty acids were first demonstrated in
vitro in late 1960s (15, 16), and also frequently seen
in the laboratory after storage of arachidonic acid in
the freezer. However, the biological significance of
these prostaglandin isomers in vivo was not un-
covered until 1990. The discovery of isoprostanes
was the starting point of a new era in the detection
and quantification of free radical-catalysed lipid
peroxidation products (1). Isoprostanes are stable
lipid peroxidation products after experimental oxi-
dative injury (4, 17). Besides having selective
bioactivity, esterified isoprostanes may also exert
biological effects within the cells where they are
formed through reaction with the adhering tissues
(3).
The formation F2-isoprostanes primarily requires
arachidonic acid, molecular oxygen and free radi-
cals. Unlike cyclooxygenase (COX)-derived primary
prostaglandins, isoprostanes are formed in situ
esterified with tissue phospholipids and subse-
quently released in free acid form following hydro-
lysis, presumably by phospholipases (18, 19). The
enzymic cleavage step is also, at least theoretically,
an important rate-limiting step for the formation
and release of free isoprostanes in the circulation,
which can be synchronized by variety of endogen-
ous or exogenous factors (20). A simplified scheme
of the formation of F2-isoprostanes from arachido-
nic acid is shown in Fig. 2.
8-Iso-prostaglandin F2a (8-iso-PGF2a; Fig. 2), a
major F2-isoprostane, and its related isomers are
augmented significantly in a number of syndromes
that are thought to be associated with oxidant
injury, and the measurement of F2-isoprostanes in
a range of tissues and body fluids is generally
regarded as a trustworthy biomarker for in vivo
determination of lipid peroxidation by free radical
pathways (1, 4, 9, 17, 20). 8-Iso-PGF2a has about
10 times higher basal levels than enzymically
produced PGF2a and the free form of this com-
pound is easily detectable in numerous body fluids
by sensitive and specific analytical approaches.
Measurement of the esterified and free isoprostanes
is suitable in the tissues, and thus could be used as
an approach to oxidative stress measurement for
target tissue injury of interest (21, 22). Specific
antibodies to the isoprostanes can also be applied
Fig. 2. Simpliﬁed scheme of 8-iso-PGF2a (F2-isoprostanes) forma-
tion from arachidonic acid by free radical catalysis. ROS: reactive
oxygen species; PGF: prostaglandin F.
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munostaining of the oxidative stress-injured tissues.
A novel study of such identification of oxidative
stress-induced cytoplasm of neurons in Alzheimer’s
pathology has recently been described (23). This
localization of bioactive isoprostanes by immunos-
taining with specific antibody is promising for
further detection of free radical-mediated tissue
damage in different diseases, and also offers possi-
bilities for the detection of therapeutic effects of
various radical scavengers in disease-related injuries.
Measuring malondialdehyde (MDA), the pre-
viously most commonly used measure of lipid
peroxidation, is much less sensitive measuring
than the increase in esterified isoprostanes in the
liver (80- versus 2.7-fold) (24). Other comparative in
vivo studies did not show any correlation between
the increase in isoprostanes and MDA levels (25,
26). Very few studies have shown a correlation
between protein oxidation and that of isoprostanes,
mainly owing to the different character of these
oxidative processes (radicals involved, timing, dura-
tion, cellular components, etc.). Even though mea-
suring isoprostanes merely reflects the oxidation
of arachidonic acid rather than of the total lipid
pool, it is thought that other lipids might have also
been oxidized in the process of lipid peroxidation.
Additional advantages of measuring isoprostanes
are that the levels of these compounds are not
exaggerated by the lipid content of the diet (27).
Nonetheless, it is vital to scrutinize when, what and
which biological samples are preferential for mea-
surement to avoid any risk of overlooking short- or
long-lasting secretion of isoprostanes. Furthermore,
incorrect collection, preservation and hazardous
preparation (during extraction, purification and
hydrolysis) of the samples before analysis are
plausible factors in the artefactual formation of
these compounds or impurity-affected analytical
errors.
The methodology for isoprostane analysis
As already mentioned, measurements of MDA,
thiobarbituric acid reactive substances (TBARS),
lipid hydroperoxides, conjugated dienes, etc., have
variousmethodologicallimitations(2,28).Although
gas chromatography and mass spectrometry (GC-
MS) were originally required for the detection and
quantification of isoprostanes, other assay methods
such as liquid chromatography (LC)mass spectro-
metry, GC-MS-MS, LC-MS-MS, radioimmunoas-
says and enzyme immunoassays (1, 2931) are now
also available. GC-MS-MS and LC-MS-MS meth-
ods require expensive and highly sensitive instru-
ments to distinguish low levels of the compound in
vivo, and well-trained technical staff, and sample
preparation and characterization are complex. The
more easily handled immunoassays are less specific
and quantitative, unless antibodies are extensively
confirmed for the cross-reactivities and other accu-
racy tests have been carried out. Nevertheless,
immunoassays have been indispensable means for
original innovation in the medical science since the
early 1970s, which is also true for isoprostane
analysis. A recent multilaboratory network study
was organized by National Institute of Environmen-
tal Health Sciences (NIEHS), NIH, USA (BOSS-II
and BOSS-III). Various oxidative stress biomarkers
measured by different methodswere used. The study
showedthatmeasurementofF2-isoprostanesinbody
fluids by different methods is indeed a consistent
biomarker of in vivo oxidative stress (32, 33).
Oxidative stress in vivo
Carbon tetrachloride (CCl4)-induced oxidative
stress is a conventional model in animals and has
been used for decades (9). CCl4 introduced orally
to experimental animals swiftly transforms to the
trichloromethyl radical (CCl3) or other radicals in
the liver that subsequently induce in vivo oxidative
stress. Measuring F2-isoprostanes using this model,
also following administration of antioxidants such
as vitamin E, has been a most important tool in
the evaluation of this biomarker of oxidative stress,
as evidenced by several such studies (21, 22, 25).
A massive amount of esterified 8-iso-PGF2a
was found in the liver tissues 2 h after the oral
administration of 2.5 ml kg
1 CCl4 to rats,
whereas the free 8-iso-PGF2a levels were quite low
(19). In an additional study, it was shown that free
8-iso-PGF2a levels increased 17-fold in plasma and
53-fold in urine from the basal levels 4 h after CCl4
(2 ml kg
1) administration to rats (25). At 6 h, free
8-iso-PGF2a levels in the plasma and urine had
increased seven-fold in plasma and 87-fold in urine
(Fig. 3). The levels of F2-isoprostanes were still
significantly elevated after 24 and 48 h compared
with the baseline after the administration of CCl4
(22). The inhibitory effect of vitamin E or other
antioxidants supported the theory that oxidative
stress was involved in increasing the F2-isopros-
tanes upon CCl4 administration (9, 21, 22).
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in, for example, cardiac infarction and stroke. It can
be induced experimentally in laboratory animals
(34). Reperfusion causes further local and remote
organ damage that is frequently observed in in-
tensive care units. Free radical formation at the
location of injury is involved in this process, which
subsequently induces oxidative stress in the whole
body (35). In a well-established experimental por-
cine model, oxidative injury was assessed by the
measurement of 8-iso-PGF2a in plasma samples
collected from both systemic circulation and the
jugular bulb, which mainly drains the brain, 2 and
5 min after cardiac arrest (36). 8-Iso-PGF2a in-
creased rapidly in both in the systemic circulation
(Fig. 4, upper panel) and jugular bulb plasma (Fig.
4, lower panel) at both time-points. In two addi-
tional studies with increased time of cardiac arrest
(8 min of ventricular fibrillation) it was shown
that 8-iso-PGF2a levels increased in jugular bulb
plasma concomitant with increases in the levels of a
COX-mediated PGF2a metabolite, hypoxanthine,
and lactate (37, 38). A further increase in cardiac
arrest time (up to 12 min of ventricular fibrillation)
led to an additional increase in 8-iso-PGF2a in the
jugular bulb plasma (35). In addition, the levels of
plasma 8-iso-PGF2a correlated with the neurologi-
cal score of the experimental animals at 24 h
following cardiac arrest and resuscitation (37).
Similarly, increased formation of F2-isoprostanes
following experimental cardiac arrest and resuscita-
tion has recently been found in brain tissue (39).
The rapid appearance of 8-iso-PGF2a in the plasma
and urine was also observed during ischaemia
reperfusion in experimental spinal cord ischaemia
in pigs (40) and canine models (41).
Taken together, these studies support the concept
that F2-isoprostanes not only increase in models of
ischaemiareperfusion, but also play a bioactive
role in the consequences of this injury. The increase
in F2-isoprostanes in the brain could be counter-
acted by the administration of various radical
scavengers such as a-phenyl-N-tert-butyl nitrone
(PBN), sulfonated a-phenyl-N-tert-butyl nitrone
(S-PBN) and methylene blue, which further sup-
ports the theory that oxidative stress is involved in
ischaemiareperfusion injury (37, 38, 42).
Isoprostanes in other human diseases
Table 1 shows a comprehensive list of diseaseswhere
isoprostanes have been measured, and this list is
growing progressively. Elevated levels in smokers
were an early indication of the involvement of
isoprostanes (68) and this has been corroborated
in several other studies (69, 111). Increased, but less
elevated levels of F2-isoprostanes have also been
demonstrated in former smokers (69).
Major controversies in this field remain over
whether isoprostanes are implicated in Alzheimer’s
disease and type 1 diabetes. In Alzheimer’s diseases,
increased levels of F2-isoprostanes have been found
specifically in the cerebrospinal fluid, neurons and
brain tissues (23, 89, 90, 112, 113). One study also
demonstrated increased levels in the urine and
plasma (91), which was not confirmed in other
studies (93, 114). The reason for this inconsistency
may be that biological samples were not taken at
identical stages of the disease or that different drugs
embroidered the outcome. The majority of the
studies with Alzheimer’s disease have revealed that
increased formation of isoprostanes is seen mainly
in neuronal tissues or in the cerebrospinal fluid.
Concerning type 1 diabetes, one report described
an elevated level of 8-iso-PGF2a in urine from
patients with type 1 diabetes (43). However, a
number of other reports showed no such differences
in patients with type 1 diabetes compared with
controls (Table 1) (4448). Young Swedish patients
Fig. 3. Levels of free 8-iso-prostaglandin F2a (8-iso-PGF2a)i n
plasma and urine at different times after oral administration of
CCl4 to rats (2 ml kg
1). ***p B0.001, **p B0.01. [Reprinted with
kind permission from Basu, 1999 (25)].
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concentrations compared with matched controls
(46). Similarly, there was no increase in the urinary
2,3-dinor-5,6-dihydro metabolite of 8-iso-PGF2a in
type 1 diabetes (45). However, one study showed
increased levels of 8-iso-PGF2a in the early phase of
diabetes onset and the level was stabilized after
1 year, in conjunction with control of the metabolic
status (44). Thus, it is assumed that differences in
the metabolic control in terms of HbA1C and fasting
glucose, hyperlipidaemia or degree of vascular
damage consecutively affect the degree of lipid
peroxidation and oxidative stress. The role of
isoprostanes in other areas, e.g. osteoporosis, is
unclear. However, it has been shown that urinary
levels of 8-iso-PGF2a are related to bone mineral
density in humans, indicating that oxidative stress
might be involved also in osteoporosis (115).
Fig. 4. Upper panel: Mixed venous plasma levels of 8-iso-prostaglandin F2a (8-iso-PGF2a) at baseline and after restoration of spontaneous
circulation (ROSC). Lower panel: Jugular bulb plasma levels of 8-iso-PGF2a at baseline and after ROSC.": Group ventricular ﬁbrillation (VF)
5; j: group VF2; ': control group. *: Signiﬁcant difference versus baseline; §: signiﬁcant difference between group VF5 versus other groups.
Values are expressed as means9SEM. [Reprinted with permission from Basu et al., 2000 (36)].
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Pathological condition Selected references Observations
Diabetes
Type 1 diabetes Davi (43, 44) Elevated
O’Byrne (45) Did not differ
Vessby (46) Did not differ
Hoeldtke (47) Did not differ
Gleisner (48) Did not differ
Type 2 diabetes Gopaul (49, 50) Elevated
Davi (43) Elevated
Murai (51) Elevated
Helmersson (52) (elderly
men 7 years’ disease duration)
Elevated
Metabolic syndrome/lipid metabolism
Hypercholesterolaemia Davi (53) Elevated
Reilly (54) Elevated
Roberts (55) Elevated
Raal (56) Did not differ
Type IIa hypercholesterolaemia Cracowski (57) Did not differ
Cardiovascular diseases
Atherosclerosis Pratico (58) Elevated
Gniwotta (59) Elevated
Mehrabi (60) Elevated
Cardiopulmonary bypass Ulus (61) Elevated
Delanty (41) Elevated
Coronary reperfusion/angioplasty/
percutaneous coronary intervention
Reilly (62) Elevated
Berg (63) Elevated
Iuliano (64) Elevated
Angiography Berg (63) Elevated
Coronary artery disease Shishehbor (65) Elevated
Heart failure Cracowski (66) Elevated
Mallat (67) Elevated
Cardiovascular risk factors
Smoking Morrow (68) Elevated
Helmersson (69) Elevated
Passive smoking Ahmadzadehfar (70) Elevated
Former smokers Helmersson (69) Elevated
Pulmonary diseases
Asthma Montuschi (71) Elevated
Wood (72) Elevated
Baraldi (73) Elevated
Acute respiratory distress syndrome Carpenter (74) Elevated
Cystic fibrosis Collins (75) Elevated
Ciabattoni (76) Elevated
Montuschi (77) Elevated
Pulmonary hypertension Cracowski (78) Elevated
Obstructive pulmonary diseases Pratico (79) Elevated
Montuschi (80) Elevated
Interstitial lung diseases Montuschi (81) Elevated
Reproductive diseases
Pre-eclampsia Morris (82) Did not differ
Ishihara (83) Did not differ
Regan (84) Did not differ
Walsh (85) Elevated
Barden (86, 87) Elevated
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with oxidative stress
In healthy aerobic organisms, the formation of
reactive radical species of diverse activity appears
to be finely tuned by the body’s efficient antioxidant
defence system. Nonetheless, once the production
exceeds the regular physiological equilibrium, the
mammalian body experiences potentially deleter-
iously distress, frequently referred to as oxidative
stress. It is rarely described whether mild or low
grade oxidative stress has any function in physiol-
ogy, apart from being seen in chronic diseases such
as diabetes, obesity and atherosclerosis, and also in
smoking. Moderately higher levels of isoprostanes
are seen in these conditions, compared with the
more pronounced response seen in acute inflamma-
tory situations.
It seems now that a mild increase in basal
isoprostanes is also a component of certain basic
physiological states such as normal pregnancy (82,
83). When an increased oxidative activity occurs as
part of a normal physiological state, it may be
considered as an ‘‘oxidative strain’’ rather than an
oxidative stress. In other words, oxidative strain
could be regarded as a condition in which increased
free radical-mediated reactions are necessary to
maintain specific functions. In such specific circum-
stances, the body requires a mild oxidative imbal-
ance. This situation is different from the chronic
low-grade inflammatory conditions in chronic
diseases, where a low but sustained increase in
F2-isoprostanes occurs (52, 69, 116), or the high
increase in F2-isoprostanes seen in chronic se-
vere inflammatory conditions, such as rheumatic
Table 1 (Continued)
Pathological condition Selected references Observations
Pregnancy with Down’s syndrome Perrone (88) Elevated
Neurodegenerative diseases
Alzheimer’s disease Montine (89, 90) Elevated
Pratico (91) Elevated
Feillet-Coudray (92) Did not differ
Montine (93, 94) Did not differ
Casadesus (23) Differed
Huntington’s disease Montine (94) Did not differ
Montine (95) Elevated
Parkinson’s diseases Fessel (96) Did not differ
Dementia with Lewy body disease Fessel (96) Did not differ
Migraine Helmersson (97) Did not differ
Spinal cord injury Monga (98) Elevated
Multiple sclerosis Mattsson (99) Elevated
Other diseases
Prostate cancer Camphausen (100) Did not differ
Haemodialysis Handelman (101) Elevated
Ikizler (102) Elevated
Kidney transplantation Cracowski (103) Did not differ
Basu (104) Elevated
Dialysis patients Lauzurica (105) Elevated
Hypertension with renovascular disease Minuz (106) Elevated
Inflammatory diseases
Rheumatoid arthritis Basu (107) Elevated
Psoriatic arthritis Basu (107) Elevated
Reactive arthritis Basu (107) Elevated
Osteoarthritis Basu (107) Elevated
Systemic sclerosis Cracowski (108) Elevated
Stein (109) Elevated
Periodontal disease Wolfram (110) Elevated
Physiological conditions
Human pregnancy Morris (82) Elevated
Ishihara (83) Elevated
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drome (ARDS) (71, 77, 81, 107).
Role of antioxidants on isoprostane formation
A central issue remaining to be elucidated is the role
of exogenous antioxidants in different human dis-
eases where oxidative stress is involved in the
pathology. This issue can be addressed indirectly
by studies of effects on reliable oxidative stress
biomarkers such as isoprostanes. In rats with CCl4-
induced hepatotoxicity, a high dose of vitamin E
(20 g kg
1 diet of all-rac-tocopheryl succinate for
3 weeks) affected non-enzymic lipid peroxidation
(21). Administration of vitamin E before the CCl4
treatment resulted in significantly lower levels of
urinary and liver free 8-iso-PGF2a. Thus, lipid
peroxidation during experimental hepatic oxidative
injury and inflammatory response could be reduced
by daily dietary supplementation of high doses of
vitamin E. It has also been shown that antioxidant
therapy ameliorated the progression of atherosclero-
sis and isoprostane formation in animal studies
(117).
Recent human studies, however, show that a-
tocopherol in varying doses (2002000 IU per day
for 8 weeks or 200 IU per day for 2 weeks) did not
affect the concentrations of F2-isoprostanes (118,
119). Vitamin E supplementation also did not affect
levels of F2-isoprostanes in moderate cigarette
smokers (120). In another study in which cigarette
smokers consumed a diet high in polyunsaturated
fat a pro-oxidant effect of supplementary vitamin E
was even observed (121). However, when hyperch-
olesterolaemic patients were treated with high doses
(8003200 IU per day), but not with lower doses
(100400 IU per day) of vitamin E, a significant
decrease in the plasma F2-isoprostane level was
noted after 16 weeks (55), as seen in the animal
studies (21). Other studies, however, have shown
that vitamin E supplementation reduced the urinary
concentration of F2-isoprostanes in patients with
type 2 diabetes (43), cystic fibrosis (76), hypercho-
lesterolaemia (53) and homozygous homocystinuria
(122), and also reduced urinary F2-isoprostane
levels in hepatic cirrhosis and alcoholic liver disease
(123).
In a mechanistic study in which the formation of
different isomers of CLA-induced F2-isoprostanes
was followed in healthy subjects, no decrease in the
urinary 8-iso-PGF2a level was seen during 4 weeks
of supplementation with vitamin E (200 IU per day)
(119). Neither did 28 days’ supplementation with
various doses of a-tocopherol (15, 100, 200 and
400 IU per day) have any effect on the basal levels of
F2-isoprostanes in healthy human subjects (124).
Together, these studies show that vitamin E supple-
mentation has a varying antioxidative effect in
studies related to different doses or patients or
population groups or stage of pathogenesis of
diseases, possibly depending on the basal lipid
peroxidation process or even the pharmacoge-
nomics in these individuals. Measurement of iso-
prostanes would be a relevant tool in the further
study of the efficacy of various antioxidants.
Oxidative modification of low-density lipopro-
teins and the subsequent formation of foam cells are
considered to affect the formation of atherosclerotic
lesions, and both in vitro and various experimental
studies show that oxidative stress is involved in all
stages of coronary artery disease (125128). How-
ever, recent large clinical trials have failed to
demonstrate any clinical outcome of antioxidant
supplementation (129). This is possibly due to the
fact that the majority of these intervention studies
neither had any reliable way of determining systemic
oxidant stress, nor recruited the patients according
to degree of oxidant stress. More studies are needed
to prove or refute the role of antioxidant therapy in
atherosclerosis. The most momentous question in
this context is whether this disease is caused by
oxidative stress or whether oxidative stress is merely
a consequence of other disease processes.
Conclusions
Oxidative stress is believed to be one of the major
processes underlying several acute or chronic dis-
eases. Isoprostanes are biologically potent free
radical-catalysed compounds, and current evidence
suggests that they are reliable in vivo biomarkers of
oxidative stress. Isoprostanes are involved in normal
physiology such as human pregnancy, as well as in
acute and chronic inflammation pathology. These
non-enzymically, rapidly formed compounds not
only are bioactive themselves, but also seem to be
useful as novel early biomarkers of oxidative stress,
and further could be applied to study the efficacy of
antioxidants and other free radical scavengers.
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